Karsten Jurchott

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. pmc Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations
    Till Krech
    Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charite, Universitatsmedizin Berlin, Chariteplatz 1, D 10117 Berlin, Germany
    BMC Cancer 10:287. 2010
  2. ncbi request reprint YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression
    Karsten Jurchott
    Max Delbruck Centrum fur Molekulare Medizin, Robert Rossle Strasse 10, 13092 Berlin, Germany
    J Biol Chem 278:27988-96. 2003
  3. ncbi request reprint Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival
    Balazs Gyorffy
    Charite, Institute of Pathology, Humboldt University, Schumannstr 20 21, Berlin D 10117, Germany
    Oncogene 24:7542-51. 2005
  4. pmc Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells
    Karsten Jurchott
    Laboratory of Molecular Tumor Pathology, Universitatsmedizin Berlin, Berlin, Germany
    PLoS Genet 6:e1001231. 2010
  5. ncbi request reprint Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients
    Ulrike Stein
    Division of Surgery and Surgical Oncology, Charite, Humboldt University, Campus Berlin Buch, Robert Rössle Hospital and Tumor Institute, Robert Rossle Strasse 10, 13092 Berlin, Germany
    J Clin Oncol 20:3282-92. 2002
  6. ncbi request reprint YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter
    Per S Holm
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Klinikum rechts der Isar, Munchen 81675, Germany
    J Biol Chem 277:10427-34. 2002
  7. pmc Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development
    Gabriel Glockzin
    Institut fuer Experimentelle Onkologie und Therapieforschung, Technische Universitaet Muenchen, Klinikum rechts der Isar, Ismaninger Str 22, 81675 Munich, Germany
    J Virol 80:3904-11. 2006

Collaborators

Detail Information

Publications7

  1. pmc Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations
    Till Krech
    Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charite, Universitatsmedizin Berlin, Chariteplatz 1, D 10117 Berlin, Germany
    BMC Cancer 10:287. 2010
    ..Here we characterize the biological effects of the PIAs SH-5 and SH-6 in colorectal cancer cell lines...
  2. ncbi request reprint YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression
    Karsten Jurchott
    Max Delbruck Centrum fur Molekulare Medizin, Robert Rossle Strasse 10, 13092 Berlin, Germany
    J Biol Chem 278:27988-96. 2003
    ..Thus, we have identified YB-1 as a cell cycle stage-specific transcription factor important for cell proliferation...
  3. ncbi request reprint Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival
    Balazs Gyorffy
    Charite, Institute of Pathology, Humboldt University, Schumannstr 20 21, Berlin D 10117, Germany
    Oncogene 24:7542-51. 2005
    ..Our approach demonstrates the significance of in vitro experiments in the development of new strategies for cancer response prediction...
  4. pmc Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells
    Karsten Jurchott
    Laboratory of Molecular Tumor Pathology, Universitatsmedizin Berlin, Berlin, Germany
    PLoS Genet 6:e1001231. 2010
    ..This suggests that MEK/ERK-dependent, YBX1-regulated target genes are involved in executing malignant properties...
  5. ncbi request reprint Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients
    Ulrike Stein
    Division of Surgery and Surgical Oncology, Charite, Humboldt University, Campus Berlin Buch, Robert Rössle Hospital and Tumor Institute, Robert Rossle Strasse 10, 13092 Berlin, Germany
    J Clin Oncol 20:3282-92. 2002
    ....
  6. ncbi request reprint YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter
    Per S Holm
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Klinikum rechts der Isar, Munchen 81675, Germany
    J Biol Chem 277:10427-34. 2002
    ..In infected cells, AdYB-1 efficiently replicated and produced infectious progeny particles. Thus, adenovirus E1B-55kDa protein and the host cell factor YB-1 act jointly to facilitate adenovirus replication in the late phase of infection...
  7. pmc Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development
    Gabriel Glockzin
    Institut fuer Experimentelle Onkologie und Therapieforschung, Technische Universitaet Muenchen, Klinikum rechts der Isar, Ismaninger Str 22, 81675 Munich, Germany
    J Virol 80:3904-11. 2006
    ..Our data suggest that the integration of YB-1 in oncolytic adenoviruses is a promising strategy for developing oncolytic vectors with enhanced potency against different malignancies...